Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.

ABSTRACT: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration. Basic and translational studies have shown that B cells and myeloid cells are critical players for the development and course of the disease. Bruton's tyrosine kinase (BTK) is essential for B cell receptor-mediated B cell activation and for normal B cell development and maturation. In addition to its role in B cells, BTK is also involved in several functions of myeloid cells. Although significant number of disease-modifying treatments (DMTs) have been approved for clinical use in MS patients, novel targeted therapies should be studied in refractory patients and patients with progressive forms of the disease. On the basis of its role in B cells and myeloid

SUBMITTER: Carnero Contentti E 

PROVIDER: S-EPMC9553159 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature